This partnership will benefit two studies, involving 1,000 Mayo Clinic patients. One study relates to immunotherapy in lung cancer, melanoma, bladder cancer, breast cancer and lymphoma, while the other assesses the efficacy of endocrine therapy in advanced breast cancer. Tempus will provide tumor sequencing, using machine learning and bioinformatics to generate data for the Mayo Clinic research teams.
Mayo Clinic’s ultimate goal is to develop biomarkers that predict the benefit of new therapeutics for cancer treatment. During the course of the study, patients will also have access to genomic results from Tempus, which physicians may use to inform treatment decisions.
More articles on health IT:
Leveraging AI for healthcare: 3 questions with digital health innovators Austin Ogilvie & Ash Damle
Northwell Health, Avizia partner for telehealth
Survey: 61% of healthcare payers, providers anticipate genomic data focus by 2020
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
